Improving Outcomes After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma in the Brentuximab Vedotin Era

Allogeneic hematopoietic cell transplantation (allo HCT) remains a valuable alternative for relapsed/refractory (R/R) Hodgkin lymphoma (HL). Data on allo HCT outcomes in the era of new HL therapies are needed. We evaluated 72 R/R HL patients who received reduced intensity conditioning (RIC) allo HCT...

全面介紹

Na minha lista:
書目詳細資料
發表在:Bone Marrow Transplant
Main Authors: Hegerova, Livia, Cao, Qing, Lazaryan, Aleksander, McClune, Brian L., Weisdorf, Daniel J., Brunstein, Claudio G., Bachanova, Veronika
格式: Artigo
語言:Inglês
出版: 2017
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5415418/
https://ncbi.nlm.nih.gov/pubmed/28134921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bmt.2016.357
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍